ResearchPoint Global Partner Announcements
Austin, TX.- February 23, 2011- ResearchPoint Global (RPG), a leading worldwide clinical research organization (CRO), announces new studies, completions and new hires for each of its members.
PivotalPivotal has recently concluded or is in the process of concluding 2 major trials in Oncology which have been either published or publicized by the Sponsor, namely:
1) A breast cancer megatrial in the node negative population with 1060 patients enrolled in 3 countries (Spain as the lead, Germany and Poland), which was submitted to the EMA and the indication for docetaxel in this setting was granted based on the results of this trial.
2) A major trial which is currently in the follow up period which has been performed in newly diagnosed advanced NSCLC patients in 3 countries (Spain as the lead, France and Italy). The study, under the acronym EURTAC, is the first study to show progression-free survival benefit of first line erlotinib in a Western population with advanced lung cancer with EGFR mutations.
P.R.I.S.M.A. has recently completed enrolment in a double-blind, placebo controlled, pulmonary arterial hypertension study. P.R.I.S.M.A.-staff has extensive experience in PAH and to date has completed 8 studies in this orphan drug indication.
ResearchPointResearchPoint has recently completed studies in the following indications: osteoporosis with an intranasal delivery system, lower back pain with a patch delivery system, kidney stones, in addition to an IVD study for the detection of prostate cancer. Additionally, ResearchPoint has been awarded new projects in a variety of indications. Included in these recent awards are two full-service medical device trials; one using isometric therapy in uncontrolled hypertensive subjects and another evaluating the incidence of deep vein thrombosis following intravenous catheter insertion. Also included are a drug study for the treatment of essential tremors, a Phase I trial evaluating a new centrally acting analgesic and a full-service proof of concept trial evaluating a skin substitute as an alternative to autografting in burn patients.
Triclinium recently announced the appointment of Piero Lamberti, MD to the position of Clinical Operations Manager, as from April 1st, 2011. Most recently, he has been Head of Medical Affairs for Europe and Canada, based in Berlin for Bayer-Schering. Dr. Lamberti began his career with Sanofi-Synthelabo as a Medical Advisor, responsible for research in CNS, Internal Medicine, Oncology and Cardiovascular products as well as Pharmacovigilance, after qualifying in medicine in Johannesburg in 1986.
"Piero's extensive medical, management and international experience and personal qualities will be significant new assets in our quest to take Triclinium, already South Africa's largest and most successful home-bred CRO, to greater heights," said founder and Managing Director Victor Strugo in his welcoming announcement.
GCTGCT is a full service regional CRO, headquarters in Princeton, NJ; conducting clinical trials across Russia and Eastern Europe is celebrating its 10-year anniversary. With this event, GCT is offering all former, present and potential clients 10% discount from their regular fees for the year. GCT maintains relationships with key opinion leaders in the many therapeutic areas and is well regarded by the sites as a CRO work within the region. Visit www.gctrials.com for more information.
ResearchPoint GlobalRPG is excited to announce the completion of its largest multi-continent study for a phase II rheumatoid arthritis study in Argentina, Bulgaria, Czech Republic, Germany, Mexico, Poland, Serbia, U.K. and the United States. The study involved approximately 300 subjects across 37 sites in the nine countries.
About ResearchPoint Global ResearchPoint Global (RPG) is a worldwide clinical organization with 23 regional offices and coverage in over 60 countries. As a proven global organization, RPG involves truly local resources to navigate regional issues and consists of high-performing teams whose principals are actively engaged in the success of each clinical program. Visit www.researchpointglobal.com for more information.